The critical drug has been developed for radiological nuclear emergencies and has been approved by Drug Controller General of India (DCGI) approval. The drug has been developed by the industry based on the technology of Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi. The drug is available under the trade name of Pru-DecorpTM and PruDecorp-MG. The formulations are used for the decontamination of Cesium & Thallium. The drug is CDSCO approved and one of the critical medicines listed by World Health Organization (WHO) for radiological & nuclear emergencies.
